The JointJYNT +5.40%63 Return-on-Tangible-Equity is 34.05% as of Mar. 2026, which is 813% above its 10-year median of 3.73. GuruFocus rates JYNT with a GF Score™ of 63/100 and a GF Value™ of $11.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 581 Healthcare Providers & Services companies, The Joint ranks better than 63.34% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. The Joint's annualized net income for the quarter that ended in Mar. 2026 was $5.20 Mil. The Joint's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $15.26 Mil. Therefore, The Joint's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 34.05%.
The historical rank and industry rank for The Joint's Return-on-Tangible-Equity or its related term are showing as below:
JYNT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -173.36 Med: 3.73 Max: 219.72
Current: 16.8
During the past 13 years, The Joint's highest Return-on-Tangible-Equity was 219.72%. The lowest was -173.36%. And the median was 3.73%.
JYNT's Return-on-Tangible-Equity is ranked better than 63.34% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 9.93
vs JYNT: 16.80
The Joint (NAS:JYNT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
The Joint Return-on-Tangible-Equity Related Terms
The Joint Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for The Joint's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JYNT vs PARK, WW, BTMD: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, The Joint's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where The Joint's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 34.05% mean?
The Joint (JYNT) has a Return-on-Tangible-Equity of 34.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The Joint and its competitors. This is 813% above median its historical median of 3.73. According to the industry distribution chart, The Joint ranks #213 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 36.7%.
Is The Joint's Return-on-Tangible-Equity too high?
The Joint's current Return-on-Tangible-Equity of 34.05% is 813% above median its 10-year median of 3.73. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 9.93. The Joint's value of 34.05% is 242.9% above this industry median. Based on the distribution chart, The Joint ranks #213 out of 581 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, The Joint has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's Return-on-Tangible-Equity compare to PARK and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #213 out of 581 companies for Return-on-Tangible-Equity. This puts The Joint in the upper half of its industry. The industry median Return-on-Tangible-Equity is 9.93. The Joint's value of 34.05% is 242.9% above this benchmark. While the company's 10-year median is 3.73 vs. the industry median of 9.93, The Joint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.93, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current Return-on-Tangible-Equity of 34.05% is 242.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The Joint and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current Return-on-Tangible-Equity is 34.05%, which is 813% above median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.11, compared to a current price of $8.81 — trading 20.7% below its estimated fair value. The current Return-on-Tangible-Equity is 34.05%, which is 813% above median its 10-year median of 3.73 and 242.9% above the Healthcare Providers & Services industry median of 9.93. The Joint's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For The Joint (JYNT), the current Return-on-Tangible-Equity is 34.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.81 is trading 20.7% below its estimated GF Value™ of $11.11.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
Return-on-Tangible-Equity: 34.05% (813% above median its 10-year median of 3.73)
GF Value™: $11.11 vs. price of $8.81 (20.7% below fair value)
Industry Position: 242.9% above the Healthcare Providers & Services median (#213 of 581)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
63GF Score
Get the complete analysis for JYNT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
